Experts Urge Researchers to Focus More on Stage IV Breast Cancer

Experts Urge Researchers to Focus More on Stage IV Breast Cancer

Much of the research that focuses on finding solutions for breast cancer goes into stages of the disease preceding Stage IV. Stage III is described as "locally advanced breast cancer," but metastatic breast cancer, or Stage IV, means the tumor cells have spread beyond the breast tissue and into other parts of the body.

It is estimated that a fifth of all breast cancer cases are either locally advanced or have spread to other parts of the body at diagnosis. In developing countries, the number can go up to 60%. Additionally, one third of early breast cancer cases will become metastatic regardless of care and treatment received. According to the American Cancer Society (ACS) the five-year survival rate after a stage 4 breast cancer diagnosis is 22 percent.

While the most pressing concern on most people's minds is getting screened and diagnosed early, experts from all over the world are urging scientists, educators, and pharmaceutical/medical companies to devote more attention to Stage IV breast cancer.

Last Friday, the international guidelines for the management of advanced breast cancer was finally published in two of the most prominent oncology journals: The Breast and Annals of Oncology. Despite these updates, industry experts are still alarmed by the lack of research and development for the following Stage I

Subscribe or to access all post and page content.

One comment

  1. Missy says:

    I am already stunned that apparently so little and money are spent on Stage IV Breast cancer (considering the severity AND the number of individuals “contracting” this advanced condition. Why (except for the “realities” of plain old MONEY. While on said topic, I do ask “upon bended knees)why our oncologists refuse to test the primary (breast) tumor after several months- infact they REFUSE to even consider this to estimate/determine whether ptimsty tumor has (shrunk) (grown) or (stayed the same size. Their comment; “We NEVER do that”- that is estimate the comparative size of the original tumor after Ibrance treatment (which was long enough) By the way, other breast cancer centers do this measurement using a variety of “methodologies”. So what gives? You aren’t supposed to know because the news is (a)good, (b) bad—grown, or(c) stays the same. Would that not be the essence of importance for the average patient? If you have a comment, love to hear from you as, for me, it simply DOESN’T COMPUTE!!!!

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.